EAM
ABCL icon

Exome Asset Management’s AbCellera Biologics ABCL Stock Holding History

Exome Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-514,900
Closed -$1.52M – 60
2024
Q2 		$1.52M Buy
+514,900
New +$1.95M 1.36% 32

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Exome Asset Management's ABCL Position: Q3 2024 in Review

Exome Asset Management sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 514,900 shares — an estimated $1.52M sold.

Exome Asset Management first reported a position in ABCL in Q2 2024 and held it in 1 quarter. The position peaked at $1.52M in Q2 2024. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Exome Asset Management reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Exome Asset Management sold 514,900 AbCellera Biologics shares in Q3 2024, an estimated $1.52M.
  • Exome Asset Management first reported a position in AbCellera Biologics in Q2 2024 and held it in 1 quarter.
  • Exome Asset Management's AbCellera Biologics position peaked at $1.52M in Q2 2024.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.